Inhibition of translation by cytotrienin A—a member of the ansamycin family

  1. Jerry Pelletier1,6
  1. 1Department of Biochemistry, McGill University, Montreal, Quebec H3G 1Y6, Canada
  2. 2Department of Biochemistry, School of Medicine, Case Western Reserve University, Cleveland, Ohio 44106, USA
  3. 3Department of System Chemotherapy and Molecular Sciences, Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto 606-8501, Japan
  4. 4Department of Molecular and Cellular Biology, UC Davis, University of California, Davis, California 95616, USA
  5. 5Chemical Biology Department, Advanced Science Institute, RIKEN, Wako-shi, Saitama 351-0198, Japan
  6. 6The Rosalind and Morris Goodman Cancer Centre, McGill University, Montreal, Quebec H3G 1Y6, Canada

Abstract

The ansamycins are a diverse and often physiologically active group of compounds that include geldanamycin and rifamycin, inhibitors of heat shock protein 90 and prokaryotic DNA-dependent RNA synthesis, respectively. Cytotrienin A is an ansamycin-type small molecule with potent antiproliferative and proapoptotic properties. Here, we report that this compound inhibits eukaryotic protein synthesis by targeting translation elongation and interfering with eukaryotic elongation factor 1A function. We also find that cytotrienin A prevents HUVEC tube formation and diminishes microvessel formation in the chorioallantoic membrane assay. These results provide a molecular understanding into cytotrienin A's previously reported properties as an anticancer apoptosis-inducing drug.

Keywords

Footnotes

  • Reprint requests to: Jerry Pelletier, McIntyre Medical Sciences Building, Room 810, 3655 Promenade Sir William Osler, McGill University, Montreal, Quebec H3G 1Y6, Canada; e-mail: jerry.pelletier{at}mcgill.ca; fax: (514) 398-7384.

  • Article published online ahead of print. Article and publication date are at http://www.rnajournal.org/cgi/doi/10.1261/rna.2307710.

  • Received June 7, 2010.
  • Accepted September 17, 2010.
| Table of Contents